116 related articles for article (PubMed ID: 32292576)
1. First-in-human study of anticancer immunotherapy drug candidate mobilan: safety, pharmacokinetics and pharmacodynamics in prostate cancer patients.
Eremina NV; Kazey VI; Mishugin SV; Leonenkov RV; Pushkar DY; Mett VL; Gudkov AV
Oncotarget; 2020 Apr; 11(14):1273-1288. PubMed ID: 32292576
[TBL] [Abstract][Full Text] [Related]
2. Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy.
Mett V; Komarova EA; Greene K; Bespalov I; Brackett C; Gillard B; Gleiberman AS; Toshkov IA; Aygün-Sunar S; Johnson C; Karasik E; Bapardekar-Nair M; Kurnasov OV; Osterman AL; Stanhope-Baker PS; Morrison C; Moser MT; Foster BA; Gudkov AV
Oncogene; 2018 Jan; 37(4):439-449. PubMed ID: 28967901
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Novel Immunomodulatory Flagellin-Like Protein FlaC in Campylobacter jejuni and Other Campylobacterales.
Faber E; Gripp E; Maurischat S; Kaspers B; Tedin K; Menz S; Zuraw A; Kershaw O; Yang I; Rautenschlein S; Josenhans C
mSphere; 2016; 1(1):. PubMed ID: 27303676
[TBL] [Abstract][Full Text] [Related]
5. Flagellin enhances tumor-specific CD8⁺ T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model.
Nguyen CT; Hong SH; Sin JI; Vu HV; Jeong K; Cho KO; Uematsu S; Akira S; Lee SE; Rhee JH
Vaccine; 2013 Aug; 31(37):3879-87. PubMed ID: 23831323
[TBL] [Abstract][Full Text] [Related]
6. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
7. Carboxyl-terminal fusion of E7 into Flagellin shifts TLR5 activation to NLRC4/NAIP5 activation and induces TLR5-independent anti-tumor immunity.
Lin KH; Chang LS; Tian CY; Yeh YC; Chen YJ; Chuang TH; Liu SJ; Leng CH
Sci Rep; 2016 Apr; 6():24199. PubMed ID: 27063435
[TBL] [Abstract][Full Text] [Related]
8. TLR5/7-mediated PI3K activation triggers epithelial-mesenchymal transition of ovarian cancer cells through WAVE3-dependent mesothelin or OCT4/SOX2 expression.
Park GB; Kim D
Oncol Rep; 2017 Nov; 38(5):3167-3176. PubMed ID: 28901470
[TBL] [Abstract][Full Text] [Related]
9. Toll-like receptor 5-mediated corneal epithelial inflammatory responses to Pseudomonas aeruginosa flagellin.
Zhang J; Xu K; Ambati B; Yu FS
Invest Ophthalmol Vis Sci; 2003 Oct; 44(10):4247-54. PubMed ID: 14507868
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors.
Marshall NA; Galvin KC; Corcoran AM; Boon L; Higgs R; Mills KH
Cancer Res; 2012 Feb; 72(3):581-91. PubMed ID: 22158905
[TBL] [Abstract][Full Text] [Related]
11. Over-activation of TLR5 signaling by high-dose flagellin induces liver injury in mice.
Xiao Y; Liu F; Yang J; Zhong M; Zhang E; Li Y; Zhou D; Cao Y; Li W; Yu J; Yang Y; Yan H
Cell Mol Immunol; 2015 Nov; 12(6):729-42. PubMed ID: 25418468
[TBL] [Abstract][Full Text] [Related]
12. Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors.
Elzey BD; Siemens DR; Ratliff TL; Lubaroff DM
Int J Cancer; 2001 Dec; 94(6):842-9. PubMed ID: 11745487
[TBL] [Abstract][Full Text] [Related]
13. Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis.
Brackett CM; Kojouharov B; Veith J; Greene KF; Burdelya LG; Gollnick SO; Abrams SI; Gudkov AV
Proc Natl Acad Sci U S A; 2016 Feb; 113(7):E874-83. PubMed ID: 26831100
[TBL] [Abstract][Full Text] [Related]
14. Inductive expression of toll-like receptor 5 (TLR5) and associated downstream signaling molecules following ligand exposure and bacterial infection in the Indian major carp, mrigal (Cirrhinus mrigala).
Basu M; Swain B; Maiti NK; Routray P; Samanta M
Fish Shellfish Immunol; 2012 Jan; 32(1):121-31. PubMed ID: 22085689
[TBL] [Abstract][Full Text] [Related]
15. Nucleoside Diphosphate Kinase-3 (
Flentie K; Gonzalez C; Kocher B; Wang Y; Zhu H; Marasa J; Piwnica-Worms D
Mol Cancer Res; 2018 Jun; 16(6):986-999. PubMed ID: 29523766
[TBL] [Abstract][Full Text] [Related]
16. Hormone Modulation of Toll-Like Receptor 5 in Cultured Human Bladder Epithelial Cells.
Foust-Wright CE; Pulliam SJ; Batalden RP; Berk TK; Weinstein MM; Wakamatsu MM; Phillippe M
Reprod Sci; 2017 May; 24(5):713-719. PubMed ID: 27651177
[TBL] [Abstract][Full Text] [Related]
17. Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer.
Agarwal N; Machiels JP; Suárez C; Lewis N; Higgins M; Wisinski K; Awada A; Maur M; Stein M; Hwang A; Mosher R; Wasserman E; Wu G; Zhang H; Zieba R; Elmeliegy M
Oncologist; 2016 May; 21(5):535-6. PubMed ID: 27091421
[TBL] [Abstract][Full Text] [Related]
18. Molecular cloning, characterization, and functional analysis of pigeon (Columba livia) Toll-like receptor 5.
Xiong D; Song L; Pan Z; Jiao X
Poult Sci; 2018 Nov; 97(11):4031-4039. PubMed ID: 29945253
[TBL] [Abstract][Full Text] [Related]
19. Two-step enhanced cancer immunotherapy with engineered
Zheng JH; Nguyen VH; Jiang SN; Park SH; Tan W; Hong SH; Shin MG; Chung IJ; Hong Y; Bom HS; Choy HE; Lee SE; Rhee JH; Min JJ
Sci Transl Med; 2017 Feb; 9(376):. PubMed ID: 28179508
[TBL] [Abstract][Full Text] [Related]
20. The Toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism.
Yang H; Brackett CM; Morales-Tirado VM; Li Z; Zhang Q; Wilson MW; Benjamin C; Harris W; Waller EK; Gudkov AV; Burdelya LG; Grossniklaus HE
Oncotarget; 2016 Jan; 7(3):2936-50. PubMed ID: 26655090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
